Research progress of a new lipid-regulating drug pemafibrate in therapeutic application
Pemafibrate,a new type of fibrates developed in Japan,was approved for marketing in Japan in June 2018.Compared with traditional fibrates,pemafibrate can combine peroxisome proliferator activated receptor α(PPARα)purposefully,and then regulate lipid metabolism effectively.Studies have shown that pemafibrate can not only improve blood lipid levels,but also regulate blood glucose,maintain liver metabolism,inhibit inflammation and thrombosis,and may have certain application value in people with diabetes,liver diseases,and cardiovascular diseases.The common adverse reactions are allergy,nasopharyngitis,creatine kinase elevation,blood uric acid elevation and so on.
万方数据
维普
